Ikonisys Announces the First Sale of the Ikoniscope20 Solution Including the Newly Added Reagents to Comprehensive Urology
22 Juin 2022 - 06:14PM
Business Wire
First full-solution sale endorsing Ikonisys
business model and paving the way for further sales
activity
Regulatory News:
Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO)
(Paris:ALIKO), a company specializing in the early and accurate
detection of cancer with a unique fully-automated solution for
medical diagnostic labs, announces the first sale of an
Ikoniscope20 digital fluorescence microscope solution together with
its optimized reagents.
As announced during the IPO of Ikonisys, the primary initial
focus of the commercialization strategy for the United States is to
convert current customers into Ikoniscope20 users. An active user
of Ikonisys’ former Ikoniscope Gen1 platform up to today,
Comprehensive Urology has decided to upgrade its system to the
Ikoniscope20 and at the same time to utilize the optimized reagents
provided by Ikonisys to perform its bladder cancer molecular
diagnosis.
Ikonisys’ business model is to sell a fully integrated solution
comprising hardware, software and consumables. Reagents, needed to
perform each single test, are an essential part of the molecular
diagnostics market. Ikonisys is offering clients optimized reagents
at a competitive rate, ensuring greater performance with the
ikoniscope20.
The Ikoniscope20 combined with Ikonisys’ FISH probes will
automate early bladder cancer diagnosis, allowing Comprehensive
Urology to perform several thousand tests per year.
Manny Iglesias, Sales Director USA of Ikonisys, said: “We
are very happy with this sale to Comprehensive Urology, a very
reputable long-term customer that has decided to migrate to the
state-of-art Ikoniscope20. We expect it will pave the way for
further sales and thus accelerate our commercial activities in the
United States and North American markets.”
Jurgen Schipper, Chief Commercial Officer of Ikonisys,
added: “This sale not only confirms the feasibility of our business
model but also demonstrates our commercial traction. We are very
confident in our business model and in the efficacy of our
solution. As announced during the IPO, our strategy is to address
KOLs first, demonstrating the efficacy of our platform and taking
advantage of the word-of-mouth, that in our industry spreads
fast.”
Issam Atoussi Chief Operating officer of Comprehensive
Urology added: “We have been using the Ikoniscope Gen1
technology for about 12 years now and are more than satisfied with
the results. Upgrading to the Ikoniscope20 will improve
performance, and the Ikonisys’ reagents ensure that we are using
its capabilities to the fullest providing the most accurate and
comprehensive results for our patients.”
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
About Comprehensive Urology Comprehensive Urology is
committed to provide convenient, expedited and cost-effective
urologic care applying best practice protocols and state-of-the-art
technology. The group has over 50 Urologists located throughout
Southeast Michigan, with 30 offices conveniently located to serve
its patients. Comprehensive Urology physicians have published over
1000 articles in peer review publications and have also
participated in hundreds of urologic presentations in over 20
foreign countries. Every year the group leads the list for the best
Top Docs in Hour magazine, with more doctors chosen than any other
group in the state.
Disclaimer This press release contains forward-looking
statements about the Company's prospects and development. These
statements are sometimes identified by the use of the future tense,
the conditional tense and forward-looking words such as "believe",
"aim to", "expect", "intend", "estimate", "believe", "should",
"could", "would" or "will" or, where appropriate, the negative of
these terms or any other similar variants or expressions. This
information is not historical data and should not be construed as a
guarantee that the facts and data set forth will occur. This
information is based on data, assumptions and estimates considered
reasonable by the Company. It is subject to change or modification
due to uncertainties relating to the economic, financial,
competitive and regulatory environment. This information contains
data relating to the Company's intentions, estimates and objectives
concerning, in particular, the market, strategy, growth, results,
financial situation and cash flow of the Company. The
forward-looking information contained in this press release is made
only as of the date of this press release. The Company does not
undertake to update any forward-looking information contained in
this press release, except as required by applicable law or
regulation. The Company operates in a competitive and rapidly
changing environment and therefore cannot anticipate all of the
risks, uncertainties or other factors that may affect its business,
their potential impact on its business or the extent to which the
materialization of any one risk or combination of risks could cause
results to differ materially from those expressed in any
forward-looking information, it being recalled that none of this
forward-looking information constitutes a guarantee of actual
results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220622005804/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024